Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 162

1.

Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial.

Reshef R, Ganetsky A, Acosta EP, Blauser R, Crisalli L, McGraw J, Frey NV, Hexner EO, Hoxie JA, Loren AW, Luger SM, Mangan J, Stadtmauer EA, Mick R, Vonderheide RH, Porter DL.

Biol Blood Marrow Transplant. 2019 Mar;25(3):515-521. doi: 10.1016/j.bbmt.2018.09.034. Epub 2018 Oct 10.

PMID:
30315941
2.

Polymorphisms in Rhesus Macaque Tetherin Are Associated with Differences in Acute Viremia in Simian Immunodeficiency Virus Δnef-Infected Animals.

Janaka SK, Tavakoli-Tameh A, Neidermyer WJ Jr, Serra-Moreno R, Hoxie JA, Desrosiers RC, Johnson RP, Lifson JD, Wolinsky SM, Evans DT.

J Virol. 2018 Oct 29;92(22). pii: e00542-18. doi: 10.1128/JVI.00542-18. Print 2018 Nov 15.

3.

Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization.

Hogan MJ, Conde-Motter A, Jordan APO, Yang L, Cleveland B, Guo W, Romano J, Ni H, Pardi N, LaBranche CC, Montefiori DC, Hu SL, Hoxie JA, Weissman D.

Virology. 2018 Jan 15;514:106-117. doi: 10.1016/j.virol.2017.10.013. Epub 2017 Nov 22.

4.

The SIV Envelope Glycoprotein, Viral Tropism, and Pathogenesis: Novel Insights from Nonhuman Primate Models of AIDS.

Swanstrom AE, Del Prete GQ, Deleage C, Elser SE, Lackner AA, Hoxie JA.

Curr HIV Res. 2018;16(1):29-40. doi: 10.2174/1570162X15666171124123116. Review.

PMID:
29173176
5.

Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis.

Moy RH, Huffman AP, Richman LP, Crisalli L, Wang XK, Hoxie JA, Mick R, Emerson SG, Zhang Y, Vonderheide RH, Porter DL, Reshef R.

Blood. 2017 Feb 16;129(7):906-916. doi: 10.1182/blood-2016-08-735076. Epub 2017 Jan 5.

6.

Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.

Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET, Petrone ME, Salantes DB, Seamon CA, Scheinfeld B, Kwan RW, Learn GH, Proschan MA, Kreider EF, Blazkova J, Bardsley M, Refsland EW, Messer M, Clarridge KE, Tustin NB, Madden PJ, Oden K, O'Dell SJ, Jarocki B, Shiakolas AR, Tressler RL, Doria-Rose NA, Bailer RT, Ledgerwood JE, Capparelli EV, Lynch RM, Graham BS, Moir S, Koup RA, Mascola JR, Hoxie JA, Fauci AS, Tebas P, Chun TW.

N Engl J Med. 2016 Nov 24;375(21):2037-2050. Epub 2016 Nov 9.

7.

Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus.

Leslie GJ, Wang J, Richardson MW, Haggarty BS, Hua KL, Duong J, Secreto AJ, Jordon AP, Romano J, Kumar KE, DeClercq JJ, Gregory PD, June CH, Root MJ, Riley JL, Holmes MC, Hoxie JA.

PLoS Pathog. 2016 Nov 17;12(11):e1005983. doi: 10.1371/journal.ppat.1005983. eCollection 2016 Nov.

8.

CCR5 interaction with HIV-1 Env contributes to Env-induced depletion of CD4 T cells in vitro and in vivo.

Tsao LC, Guo H, Jeffrey J, Hoxie JA, Su L.

Retrovirology. 2016 Mar 29;13:22. doi: 10.1186/s12977-016-0255-z.

9.

Derivation and Characterization of a CD4-Independent, Non-CD4-Tropic Simian Immunodeficiency Virus.

Swanstrom AE, Haggarty B, Jordan APO, Romano J, Leslie GJ, Aye PP, Marx PA, Lackner AA, Del Prete GQ, Robinson JE, Betts MR, Montefiori DC, LaBranche CC, Hoxie JA.

J Virol. 2016 Apr 29;90(10):4966-4980. doi: 10.1128/JVI.02851-15. Print 2016 May 15.

10.

Elite Control, Gut CD4 T Cell Sparing, and Enhanced Mucosal T Cell Responses in Macaca nemestrina Infected by a Simian Immunodeficiency Virus Lacking a gp41 Trafficking Motif.

Breed MW, Elser SE, Torben W, Jordan AP, Aye PP, Midkiff C, Schiro F, Sugimoto C, Alvarez-Hernandez X, Blair RV, Somasunderam A, Utay NS, Kuroda MJ, Pahar B, Wiseman RW, O'Connor DH, LaBranche CC, Montefiori DC, Marsh M, Li Y, Piatak M Jr, Lifson JD, Keele BF, Fultz PN, Lackner AA, Hoxie JA.

J Virol. 2015 Oct;89(20):10156-75. doi: 10.1128/JVI.01134-15. Epub 2015 Jul 29.

11.

Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy-treated macaques.

Santangelo PJ, Rogers KA, Zurla C, Blanchard EL, Gumber S, Strait K, Connor-Stroud F, Schuster DM, Amancha PK, Hong JJ, Byrareddy SN, Hoxie JA, Vidakovic B, Ansari AA, Hunter E, Villinger F.

Nat Methods. 2015 May;12(5):427-32. doi: 10.1038/nmeth.3320. Epub 2015 Mar 9.

12.

Mutations in HIV-1 envelope that enhance entry with the macaque CD4 receptor alter antibody recognition by disrupting quaternary interactions within the trimer.

Boyd DF, Peterson D, Haggarty BS, Jordan AP, Hogan MJ, Goo L, Hoxie JA, Overbaugh J.

J Virol. 2015 Jan 15;89(2):894-907. doi: 10.1128/JVI.02680-14. Epub 2014 Nov 5.

13.

Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor.

Pegu A, Yang ZY, Boyington JC, Wu L, Ko SY, Schmidt SD, McKee K, Kong WP, Shi W, Chen X, Todd JP, Letvin NL, Huang J, Nason MC, Hoxie JA, Kwong PD, Connors M, Rao SS, Mascola JR, Nabel GJ.

Sci Transl Med. 2014 Jul 2;6(243):243ra88. doi: 10.1126/scitranslmed.3008992.

14.

Identification and characterization of a macrophage-tropic SIV envelope glycoprotein variant in blood from early infection in SIVmac251-infected macaques.

Yen PJ, Mefford ME, Hoxie JA, Williams KC, Desrosiers RC, Gabuzda D.

Virology. 2014 Jun;458-459:53-68. doi: 10.1016/j.virol.2014.03.024. Epub 2014 May 8.

15.

Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virions.

Bastian AR, Contarino M, Bailey LD, Aneja R, Moreira DR, Freedman K, McFadden K, Duffy C, Emileh A, Leslie G, Jacobson JM, Hoxie JA, Chaiken I.

Retrovirology. 2013 Dec 13;10:153. doi: 10.1186/1742-4690-10-153.

16.

Quantification of entry phenotypes of macrophage-tropic HIV-1 across a wide range of CD4 densities.

Joseph SB, Arrildt KT, Swanstrom AE, Schnell G, Lee B, Hoxie JA, Swanstrom R.

J Virol. 2014 Feb;88(4):1858-69. doi: 10.1128/JVI.02477-13. Epub 2013 Dec 4.

17.

A single amino acid mutation in the envelope cytoplasmic tail restores the ability of an attenuated simian immunodeficiency virus mutant to deplete mucosal CD4+ T cells.

Breed MW, Jordan AP, Aye PP, Sugimoto C, Alvarez X, Kuroda MJ, Pahar B, Keele BF, Hoxie JA, Lackner AA.

J Virol. 2013 Dec;87(23):13048-52. doi: 10.1128/JVI.02126-13. Epub 2013 Sep 11.

18.

CD4+ T cells support production of simian immunodeficiency virus Env antibodies that enforce CD4-dependent entry and shape tropism in vivo.

Francella N, Gwyn SE, Yi Y, Li B, Xiao P, Elliott ST, Ortiz AM, Hoxie JA, Paiardini M, Silvestri G, Derdeyn CA, Collman RG.

J Virol. 2013 Sep;87(17):9719-32. doi: 10.1128/JVI.01254-13. Epub 2013 Jul 3.

19.

Translating social and behavioral science research to the AIDS epidemic: a center for AIDS research perspective.

Curran JW, Hoxie JA.

J Acquir Immune Defic Syndr. 2013 Jun 1;63 Suppl 1:S4-5. doi: 10.1097/QAI.0b013e3182921525.

20.

Loss of a tyrosine-dependent trafficking motif in the simian immunodeficiency virus envelope cytoplasmic tail spares mucosal CD4 cells but does not prevent disease progression.

Breed MW, Jordan AP, Aye PP, Lichtveld CF, Midkiff CC, Schiro FR, Haggarty BS, Sugimoto C, Alvarez X, Sandler NG, Douek DC, Kuroda MJ, Pahar B, Piatak M Jr, Lifson JD, Keele BF, Hoxie JA, Lackner AA.

J Virol. 2013 Feb;87(3):1528-43. doi: 10.1128/JVI.01928-12. Epub 2012 Nov 14.

21.

Novel cell and gene therapies for HIV.

Hoxie JA, June CH.

Cold Spring Harb Perspect Med. 2012 Oct 1;2(10). pii: a007179. doi: 10.1101/cshperspect.a007179. Review.

22.

Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.

Reshef R, Luger SM, Hexner EO, Loren AW, Frey NV, Nasta SD, Goldstein SC, Stadtmauer EA, Smith J, Bailey S, Mick R, Heitjan DF, Emerson SG, Hoxie JA, Vonderheide RH, Porter DL.

N Engl J Med. 2012 Jul 12;367(2):135-45. doi: 10.1056/NEJMoa1201248.

23.

Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.

Wu X, Wang C, O'Dell S, Li Y, Keele BF, Yang Z, Imamichi H, Doria-Rose N, Hoxie JA, Connors M, Shaw GM, Wyatt RT, Mascola JR.

J Virol. 2012 May;86(10):5844-56. doi: 10.1128/JVI.07139-11. Epub 2012 Mar 14.

24.

Three-dimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins determined by using cryo-electron tomography.

White TA, Bartesaghi A, Borgnia MJ, de la Cruz MJ, Nandwani R, Hoxie JA, Bess JW, Lifson JD, Milne JL, Subramaniam S.

J Virol. 2011 Dec;85(23):12114-23. doi: 10.1128/JVI.05297-11. Epub 2011 Sep 21.

25.

Structure-based identification and neutralization mechanism of tyrosine sulfate mimetics that inhibit HIV-1 entry.

Acharya P, Dogo-Isonagie C, LaLonde JM, Lam SN, Leslie GJ, Louder MK, Frye LL, Debnath AK, Greenwood JR, Luongo TS, Martin L, Watts KS, Hoxie JA, Mascola JR, Bewley CA, Kwong PD.

ACS Chem Biol. 2011 Oct 21;6(10):1069-77. doi: 10.1021/cb200068b. Epub 2011 Aug 5.

26.

High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses.

Pollara J, Hart L, Brewer F, Pickeral J, Packard BZ, Hoxie JA, Komoriya A, Ochsenbauer C, Kappes JC, Roederer M, Huang Y, Weinhold KJ, Tomaras GD, Haynes BF, Montefiori DC, Ferrari G.

Cytometry A. 2011 Aug;79(8):603-12. doi: 10.1002/cyto.a.21084. Epub 2011 Jul 6.

27.

An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum.

Ferrari G, Pollara J, Kozink D, Harms T, Drinker M, Freel S, Moody MA, Alam SM, Tomaras GD, Ochsenbauer C, Kappes JC, Shaw GM, Hoxie JA, Robinson JE, Haynes BF.

J Virol. 2011 Jul;85(14):7029-36. doi: 10.1128/JVI.00171-11. Epub 2011 May 4.

28.

Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases.

Wilen CB, Wang J, Tilton JC, Miller JC, Kim KA, Rebar EJ, Sherrill-Mix SA, Patro SC, Secreto AJ, Jordan AP, Lee G, Kahn J, Aye PP, Bunnell BA, Lackner AA, Hoxie JA, Danet-Desnoyers GA, Bushman FD, Riley JL, Gregory PD, June CH, Holmes MC, Doms RW.

PLoS Pathog. 2011 Apr;7(4):e1002020. doi: 10.1371/journal.ppat.1002020. Epub 2011 Apr 14.

29.

Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure.

White TA, Bartesaghi A, Borgnia MJ, Meyerson JR, de la Cruz MJ, Bess JW, Nandwani R, Hoxie JA, Lifson JD, Milne JL, Subramaniam S.

PLoS Pathog. 2010 Dec 23;6(12):e1001249. doi: 10.1371/journal.ppat.1001249.

30.

Circulating human CD4 and CD8 T cells do not have large intracellular pools of CCR5.

Pilch-Cooper HA, Sieg SF, Hope TJ, Koons A, Escola JM, Offord R, Veazey RS, Mosier DE, Clagett B, Medvik K, Jadlowsky JK, Chance MR, Kiselar JG, Hoxie JA, Collman RG, Riddick NE, Mercanti V, Hartley O, Lederman MM.

Blood. 2011 Jul 28;118(4):1015-9. doi: 10.1182/blood-2010-05-282509. Epub 2010 Nov 10.

31.

Distinct molecular pathways to X4 tropism for a V3-truncated human immunodeficiency virus type 1 lead to differential coreceptor interactions and sensitivity to a CXCR4 antagonist.

Del Prete GQ, Leslie GJ, Haggarty B, Jordan AP, Romano J, Hoxie JA.

J Virol. 2010 Sep;84(17):8777-89. doi: 10.1128/JVI.00333-10. Epub 2010 Jun 23.

32.

Toward an antibody-based HIV-1 vaccine.

Hoxie JA.

Annu Rev Med. 2010;61:135-52. doi: 10.1146/annurev.med.60.042507.164323. Review.

PMID:
19824826
33.

Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4.

Agrawal-Gamse C, Lee FH, Haggarty B, Jordan AP, Yi Y, Lee B, Collman RG, Hoxie JA, Doms RW, Laakso MM.

J Virol. 2009 Nov;83(21):11005-15. doi: 10.1128/JVI.01238-09. Epub 2009 Aug 19.

34.

Derivation and characterization of a simian immunodeficiency virus SIVmac239 variant with tropism for CXCR4.

Del Prete GQ, Haggarty B, Leslie GJ, Jordan AP, Romano J, Wang N, Wang J, Holmes MC, Montefiori DC, Hoxie JA.

J Virol. 2009 Oct;83(19):9911-22. doi: 10.1128/JVI.00533-09. Epub 2009 Jul 15.

35.

Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain.

Wu L, Zhou T, Yang ZY, Svehla K, O'Dell S, Louder MK, Xu L, Mascola JR, Burton DR, Hoxie JA, Doms RW, Kwong PD, Nabel GJ.

J Virol. 2009 May;83(10):5077-86. doi: 10.1128/JVI.02600-08. Epub 2009 Mar 4.

36.

Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor.

Nolan KM, Del Prete GQ, Jordan AP, Haggarty B, Romano J, Leslie GJ, Hoxie JA.

J Virol. 2009 Apr;83(8):3798-809. doi: 10.1128/JVI.01751-08. Epub 2009 Feb 4.

37.

Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma.

Davis KL, Bibollet-Ruche F, Li H, Decker JM, Kutsch O, Morris L, Salomon A, Pinter A, Hoxie JA, Hahn BH, Kwong PD, Shaw GM.

J Virol. 2009 Feb;83(3):1240-59. doi: 10.1128/JVI.01743-08. Epub 2008 Nov 19.

38.

HIV vaccine research: the way forward.

Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, Hoxie JA, Martin M, Overbaugh J, Watkins DI, Mahmoud A, Greene WC.

Science. 2008 Jul 25;321(5888):530-2. doi: 10.1126/science.1161000.

PMID:
18653883
39.

Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization.

Crooks ET, Jiang P, Franti M, Wong S, Zwick MB, Hoxie JA, Robinson JE, Moore PL, Binley JM.

Virology. 2008 Aug 1;377(2):364-78. doi: 10.1016/j.virol.2008.04.045. Epub 2008 Jun 9.

40.
41.

Tuberculosis and HIV coinfection: genesis of the supplement and sponsors' contribution.

Hoxie JA, Miller V, Walker B.

J Infect Dis. 2007 Aug 15;196 Suppl 1:S4. No abstract available.

PMID:
17624824
42.

V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.

Laakso MM, Lee FH, Haggarty B, Agrawal C, Nolan KM, Biscone M, Romano J, Jordan AP, Leslie GJ, Meissner EG, Su L, Hoxie JA, Doms RW.

PLoS Pathog. 2007 Aug 24;3(8):e117.

43.

Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists.

Lin G, Bertolotti-Ciarlet A, Haggarty B, Romano J, Nolan KM, Leslie GJ, Jordan AP, Huang CC, Kwong PD, Doms RW, Hoxie JA.

J Virol. 2007 Sep;81(18):9956-66. Epub 2007 Jul 3.

44.

Vaccine-delivered HIV envelope inhibits CD4(+) T-cell activation, a mechanism for poor HIV vaccine responses.

Fernando K, Hu H, Ni H, Hoxie JA, Weissman D.

Blood. 2007 Mar 15;109(6):2538-44. Epub 2006 Dec 7.

45.

A conserved dileucine motif mediates clathrin and AP-2-dependent endocytosis of the HIV-1 envelope protein.

Byland R, Vance PJ, Hoxie JA, Marsh M.

Mol Biol Cell. 2007 Feb;18(2):414-25. Epub 2006 Nov 15.

46.

A plea for justice for jailed medical workers.

Ahuja SK, Aiuti F, Berkhout B, Biberfeld P, Burton DR, Colizzi V, Deeks SG, Desrosiers RC, Dierich MP, Doms RW, Emerman M, Gallo RC, Girard M, Greene WC, Hoxie JA, Hunter E, Klein G, Korber B, Kuritzkes DR, Lederman MM, Malim MH, Marx PA, McCune JM, McMichael A, Miller C, Miller V, Montagnier L, Montefiori DC, Moore JP, Nixon DF, Overbaugh J, Pauza CD, Richman DD, Saag MS, Sattentau Q, Schooley RT, Shattock R, Shaw GM, Stevenson M, Trkola A, Wainberg MA, Weiss RA, Wolinsky S, Zack JA.

Science. 2006 Nov 10;314(5801):924-5. Epub 2006 Oct 24. No abstract available.

PMID:
17062652
47.

DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets.

Chaipan C, Soilleux EJ, Simpson P, Hofmann H, Gramberg T, Marzi A, Geier M, Stewart EA, Eisemann J, Steinkasserer A, Suzuki-Inoue K, Fuller GL, Pearce AC, Watson SP, Hoxie JA, Baribaud F, Pöhlmann S.

J Virol. 2006 Sep;80(18):8951-60.

49.

Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail.

Wyss S, Dimitrov AS, Baribaud F, Edwards TG, Blumenthal R, Hoxie JA.

J Virol. 2005 Oct;79(19):12231-41.

50.

Modification of a viral envelope glycoprotein cell-cell fusion assay by utilizing plasmid encoded bacteriophage RNA polymerase.

Lin G, Murphy SL, Gaulton GN, Hoxie JA.

J Virol Methods. 2005 Sep;128(1-2):135-42.

PMID:
15941597

Supplemental Content

Loading ...
Support Center